Bayesian Bivariate Subgroup Analysis for Risk-Benefit Evaluation

08/11/2018
by   Nicholas C. Henderson, et al.
0

Subgroup analysis is a frequently used tool for evaluating heterogeneity of treatment effect and heterogeneity in treatment harm across observed baseline patient characteristics. While treatment efficacy and adverse event measures are often reported separately for each subgroup, analyzing their within-subgroup joint distribution is critical for better informed patient decision-making. In this paper, we describe Bayesian models for performing a subgroup analysis to compare the joint occurrence of a primary endpoint and an adverse event between two treatment arms. Our approaches emphasize estimation of heterogeneity in this joint distribution across subgroups, and our approaches directly accommodate subgroups with small numbers of observed primary and adverse event combinations. In addition, we describe several ways in which our models may be used to generate interpretable summary measures of benefit-risk tradeoffs for each subgroup. The methods described here are illustrated throughout using a large cardiovascular trial (N = 9,361) investigating the efficacy of an intervention for reducing systolic blood pressure to a lower-than-usual target.

READ FULL TEXT
research
07/15/2022

Treatment Heterogeneity for Survival Outcomes

Estimation of conditional average treatment effects (CATEs) plays an ess...
research
01/02/2021

A statistical method for estimating the no-observed-adverse-event-level

In toxicological risk assessment the benchmark dose (BMD) is recommended...
research
09/17/2022

Using a Surrogate with Heterogeneous Utility to Test for a Treatment Effect

The primary benefit of identifying a valid surrogate marker is the abili...
research
06/08/2022

Bayesian multivariate logistic regression for superiority and inferiority decision-making under treatment heterogeneity

The effects of a treatment may differ between patients with different ch...
research
10/31/2022

Can the potential benefit of individualizing treatment be assessed using trial summary statistics alone?

Individualizing treatment assignment can improve outcomes for diseases w...
research
08/29/2022

Methodological concerns about 'concordance-statistic for benefit' as a measure of discrimination in treatment benefit prediction

Prediction algorithms that quantify the expected benefit of a given trea...

Please sign up or login with your details

Forgot password? Click here to reset